Trial Profile

A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine in Healthy Adults

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 26 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baiya SARS CoV 2 Vax 2 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Baiya Phytopharm

Most Recent Events

23 May 2023 Planned End Date changed from 1 Jan 2024 to 10 Apr 2024.
23 May 2023 Planned primary completion date changed from 1 May 2023 to 29 May 2023.
22 Dec 2022 Planned End Date changed from 1 May 2023 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com